Hypertensive Label Changes Could Remedy Under-Treatment Problem -Cmte
Executive Summary
More explicit dosing instructions in labeling might be the best way to urge physicians to more aggressively manage the under-treated hypertensive population, FDA's Cardio-Renal Advisory Committee said at an April 18 meeting to review a first-line claim for Bristol-Myers Squibb's Avalide